Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies.
Iain B McInnesPhillip J MeaseYoshiya TanakaLaure GossecM Elaine HusniLars Erik KristensenRichard B WarrenBarbara InkRajan BajracharyaJason CoarseAlice B GottliebPublished in: ACR open rheumatology (2024)
Treatment with bimekizumab demonstrated consistent, sustained efficacy to 52 weeks in bDMARD-naïve and TNFi-IR patients with PsA and was well tolerated, irrespective of concomitant MTX.